drugset / Trial / NCT01235923
Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants
Phase 2
Completed
20 enrolled
University of New Mexico
National Center for Research Resources (NCRR) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements. Dosing usually occurs three times a week, but extended dosing schedules have been successful in adults. The investigators assessed weekly Epo dosing in preterm infants compared to standard three times weekly dosing.
Timeline
- Start
- 2006-04
- Primary completion
- 2009-03
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Epo | Protein / enzyme biologic | 400 iu/kg | Subcutaneous |
| Comparator | Epo | Protein / enzyme biologic | 1200 iu/kg | Subcutaneous |
Indications
No indication recorded.